[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.

Inclusion Criteria:

• Participants will be 18 years of age or older
• History of gynecologic cancer.
• Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy
• Female participants of child-bearing potential must have a negative urine or serum pregnancy test at the time of the screening visit.
• Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific procedures.
• Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician.

Exclusion Criteria

• Females who are pregnant or breast feeding at the time of screening will not be eligible for this study.
• Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
• Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subjects safety or successful participation in the study.
• Unwilling or unable to provide informed consent